Journal article
Telmisartan, ramipril, or both in high-risk Chinese patients: analysis of ONTARGET China data.
Abstract
BACKGROUND: The results from the ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) indicated that the angiotensin-receptor blocker telmisartan was not inferior to the angiotensin-converting-enzyme inhibitor ramipril in reducing the composite endpoint of cardiovascular death, myocardial infarction, stroke or hospitalization for congestive heart failure in high-risk patients, and telmisartan was …
Authors
Yu L-T; Zhu J; Tan H-Q; Wang G-G; Teo KK; Liu L-S
Journal
Chinese Medical Journal, Vol. 124, No. 12, pp. 1763–1768
Publication Date
June 2011
ISSN
0366-6999